Bioventus, Inc. (BVS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$14.07-2.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BVS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -7.3% |
| Our one-year growth estimate | diamond | 8.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 15.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
BVS — earnings in line
Dated 2026-08-05
Results of Operations and Financial Condition. On August 5, 2026, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 27, 2026 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act…
Why it matters: Strong cash flow supports debt reduction and overall financial health.
Supportive ifCash from operations reported above $20 million in Q3.
Worry ifCash from operations reported below $15 million in Q3.
Why it matters: Pain Treatments revenue growth below 10% may indicate challenges in this key segment. This could affect overall performance and strategy.
Worry ifPain Treatments revenue growth reported below 10% year over year.
Less concerning ifPain Treatments revenue growth meets or exceeds 10% year over year.
Why it matters: An increase shows strong financial performance. It also shows confidence in future earnings.
Supportive ifManagement raises Adjusted EPS guidance to more than $0.79.
Worry ifManagement keeps or lowers Adjusted EPS guidance to less than $0.75.
Why it matters: Meeting cash from operations guidance shows good financial health. This can boost investor confidence.
Supportive ifCash from operations reported at $89M or higher for 2026.
Worry ifCash from operations falls below $84M for 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$223 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $404 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,751 loss on $10,000 · 27.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If revenue growth falls below 6%, it may signal weakening demand. This could impact future guidance and investor confidence.
Worry ifQ3 revenue growth reported below 6% year over year.
Less concerning ifQ3 revenue growth meets or exceeds 6% year over year.
Why it matters: A drop in adjusted EPS shows profit problems. This could hurt investor trust.
Worry ifAdjusted EPS reported below $0.75 for 2026.
Less concerning ifAdjusted EPS reported at or above $0.75 for 2026.
Why it matters: Reaffirming guidance shows confidence in growth. It gives investors hope for future performance.
Supportive ifManagement reaffirms 2026 revenue guidance of $600M to $610M.
Worry ifManagement cuts the revenue guidance for 2026.
Why it matters: If revenue growth speeds up, it could signal a positive shift for Bioventus.
Supportive ifHealth Care sector revenue growth speeds up to over 10% each year.
Worry ifRevenue growth remains below 10% year over year.
Why it matters: This report will provide updates on revenue and cash flow. It is key for assessing growth.
Watch forEarnings report shows revenue growth or cash flow improvement.
Also watch forEarnings report shows further revenue decline or cash flow issues.
Why it matters: Cash from operations below $84 million may indicate cash flow issues. This could affect the company's ability to reduce debt and invest in growth.
Worry ifCash from operations was less than $84 million.
Less concerning ifCash from operations reported at or above $84 million.
Why it matters: Earnings results will show if Bioventus keeps its positive trend after the last earnings beat.
Watch forEarnings per share exceeds $0.75 in Q2 2026.
Also watch forEarnings per share falls below $0.75 in Q2 2026.
Why it matters: Reaffirming guidance shows stability. This could make investors feel better.
Supportive ifManagement reaffirms revenue guidance at $600M-$610M for 2026.
Worry ifManagement lowers revenue guidance to less than $600M.